J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years.

Understanding reuse rights and copyright compliance is critical, particularly in today’s ever-evolving technological ...

Shorter trial authorisation timelines for ATMP trials in the US are an advantage for biotechs, say experts. Although the ...

Ahead of World Tuberculosis Day on 24 March, the WHO has said that global funding cuts are curtailing efforts to fight the ...

Clinical trials must use effective electronic data capture platforms that prioritise data integrity and comply with ...

The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing interest.

Servier and Black Diamond Therapeutics have signed a licencing agreement for targeted therapy, BDTX-4933, aimed at addressing ...